A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations

This study is testing a new experimental drug called SW-682 to see how well it works and how safe it is for people with advanced solid tumors. It is specifically looking for patients whose cancers have certain gene changes, known as Hippo pathway mutations, which might help the drug work more effectively.

This study is for adults with advanced or spreading solid cancers that have not responded well to standard treatments like chemotherapy or radiation. You will need to have a lab-confirmed genetic test showing specific mutations, such as those in the NF2 gene or the Hippo pathway.

Participants will take the experimental medication by mouth at home in 28-day cycles. During the study, you will have regular check-ins with the research team to monitor your health, ensure the dose is right, and see how your cancer responds to the treatment.

The study is currently recruiting patients at medical centers in Scottsdale, Arizona, as well as La Jolla and Los Angeles, California. Please talk to your doctor to see if one of these locations is a good fit for you.